Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

26 to 50 of 224 results

Globavir to seek approval and launch of novel Ebola treatment by year-end

Globavir to seek approval and launch of novel Ebola treatment by year-end

19-08-2014

Privately-held US biotech firm Globavir Biosciences said yesterday that it intends to develop its lead…

Antibiotics and Infectious diseasesGBV006Globavir BiosciencesMarkets & MarketingPharmaceuticalRegulationRest of the WorldTropical diseasesUSA

Boehringer Ingelheim acquires licensing rights for Artilysin technology

Boehringer Ingelheim acquires licensing rights for Artilysin technology

13-08-2014

Artilysin, a new and innovative technological approach in the fight against pathogenic and multi-resistant…

Antibiotics and Infectious diseasesArtilysinBoehringer IngelheimGermanyLicensingLysando AGPharmaceutical

FDA approves The Medicines Company's Orbactiv for use in ABSSSIs

FDA approves The Medicines Company's Orbactiv for use in ABSSSIs

07-08-2014

The Food and Drug Administration has approved The Medicines Company’s Orbactiv (oritavancin) for injection…

Antibiotics and Infectious diseasesOrbactivoritavancinPharmaceuticalRegulationThe Medicines CompanyUSA

Biota tanks as flu drug candidate disappoints

Biota tanks as flu drug candidate disappoints

04-08-2014

USA-based Biota Pharmaceuticals saw its shares slump 29% to a record low of $2.29 on Friday, after the…

Anti-viralsAntibiotics and Infectious diseasesBiota PharmaceuticalsFinancialPharmaceuticalResearchUSA

Novartis' KAE609 effective in uncomplicated malaria patients

Novartis' KAE609 effective in uncomplicated malaria patients

31-07-2014

Swiss drug major Novartis says that results published in the New England Journal of Medicine show that…

Antibiotics and Infectious diseasesJoseph JimenezKAE609NovartisPharmaceuticalPlasmodiumResearchSwitzerland

Durata out-licenses dalbavancin to Angelini for certain territories

Durata out-licenses dalbavancin to Angelini for certain territories

30-07-2014

USA-based Durata Therapeutics says its Dutch subsidiary entered into a license and supply agreement with…

AngeliniAntibiotics and Infectious diseasesDalvanceDurata TherapeuticsEuropeLicensingPharmaceutical

New study identifies potential alternatives to Gilead’s Sovaldi

New study identifies potential alternatives to Gilead’s Sovaldi

29-07-2014

There are multiple hepatitis treatments in development that may serve as potential alternatives to Gilead…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbdaclatasvirGilead SciencesGlobalHepatitis C treatmentMarkets & MarketingmericitabinePharmaceuticalRocheSovaldi

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

New Zealand to fund Norgine’s Xifaxan for hepatic encephalopathy

15-07-2014

New Zealand Pharmaceutical Management Agency PHARMAC has awarded a tender to Netherlands-headquartered…

Antibiotics and Infectious diseasesFinancialHealthcareNew ZealandNorginePharmaceuticalXifaxan

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Research shows OPAT drugs should be first used on inpatients to penetrate the market

Research shows OPAT drugs should be first used on inpatients to penetrate the market

11-07-2014

While more than three quarters of surveyed infectious disease specialists are willing to prescribe Durata’s…

AntibioticsAntibiotics and Infectious diseasesDalvanceDecision Resources GrouporitavancinOritavancinPharmaceuticalResearch

Astellas submits NDA for isavuconazole to treat deadly fungal infections

Astellas submits NDA for isavuconazole to treat deadly fungal infections

10-07-2014

Japanese drug major Astellas Pharma has submitted a New Drug Application to the US Food and Drug Administration,…

Antibiotics and Infectious diseasesAntifungal therapiesAspergillosisAstellas PharmaBiologyFungal diseasesImmunologicalsInvasive aspergillosisisavuconazoleJapanMycologyPharmaceuticalRegulationZygomycosis

UK Ministers “must stop unnecessary use of antibiotics”

UK Ministers “must stop unnecessary use of antibiotics”

07-07-2014

A wide-raging report published today by the UK House of Commons Science and Technology Select Committee…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalPoliticsResearchUK

GlobalData says UK fears over antibiotic resistance is

GlobalData says UK fears over antibiotic resistance is "valid conclusion"

04-07-2014

Earlier this week, UK Prime Minister David Cameron revealed the formation of an independent review panel…

Antibiotics and Infectious diseasesEuropePharmaceuticalResearchUSA

UK launches fresh fight against antimicrobial resistance

UK launches fresh fight against antimicrobial resistance

02-07-2014

The UK prime minister David Cameron has said he wants Britain to lead the way in the battle against antimicrobial…

Antibiotics and Infectious diseasesHealthcarePharmaceuticalUK

Transcept and Paratek join forces in reverse takeover

Transcept and Paratek join forces in reverse takeover

01-07-2014

US pharma company Transcept Pharmaceuticals and privately-held biopharmaceutical company Paratek Pharmaceuticals…

Antibiotics and Infectious diseasesMergers & AcquisitionsParatek PharmaceuticalsPharmaceuticalTranscept PharmaUSA

FDA calls for additional Ph III study for Basilea’s ceftobiprole

FDA calls for additional Ph III study for Basilea’s ceftobiprole

26-06-2014

Swiss drugmaker Basilea Pharmaceutica saw its shares drop as much as 12% yesterday, after it revealed…

Antibiotics and Infectious diseasesBacteriaBasilea PharmaceuticaceftobiproleHealth Medical PharmaHealth Medical PharmaisavuconazoleMedicinePharmaceuticalRegulationTreatment of pneumoniaUSA

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

BioAlliance Pharma signs deal with EMS for Sitavig in Brazil

26-06-2014

French oncology specialist BioAlliance Pharma SA has announced a license agreement for Sitavig (acyclovir…

Antibiotics and Infectious diseasesBioAlliance PharmaBrazilLicensingPharmaceuticalSitavig

Cubist’s Sivextro gets FDA approval for serious skin infections

Cubist’s Sivextro gets FDA approval for serious skin infections

22-06-2014

The US Food and Drug Administration has approved Cubist Pharmaceuticals’ Sivextro (tedizolid phosphate)…

Antibiotics and Infectious diseasesCubist PharmaceuticalsPharmaceuticalRegulationSivextroUSA

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

FDA accepts Cubist’s ceftolozane/tazobactam NDA with Priority Review

20-06-2014

The US Food and Drug Administration has accepted Cubist Pharmaceuticals’ New Drug Application for its…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsPharmaceuticalRegulationtazobactamUSA

UK’s Summit sets up operations in the USA

UK’s Summit sets up operations in the USA

17-06-2014

UK drug discovery firm Summit, which is focused on therapies for Duchenne muscular dystrophy and Clostridium…

Antibiotics and Infectious diseasesBoardroomManagementPharmaceuticalRare diseasesResearchSummit PharmaceuticalsUSA

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

Evotec to acquire Euprotec to establish an anti-infectives platform

Evotec to acquire Euprotec to establish an anti-infectives platform

29-05-2014

Germany’s Evotec says it has acquired all the shares in Euprotec Ltd, a UK-based specialist contract…

Anti-infective drug discovery servicesAntibiotics and Infectious diseasesBusiness FinanceDiseaseEvotecHealth Medical PharmaMergers & AcquisitionsPharmaceuticalRecognised leader

FDA approves Durata’s Dalvance to treat skin infections

26-05-2014

The US Food and Drug Administration last Friday approved Durata Therapeutics’ Dalvance (dalbavancin),…

Antibiotics and Infectious diseasesDalvanceDurata TherapeuticsPharmaceuticalRegulationUSA

26 to 50 of 224 results

Back to top